Close Menu

NEW YORK – Bristol Myers Squibb on Friday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive recommendation for two of its immune checkpoint inhibitors, nivolumab (Opdivo) and ipilimumab (Yervoy), in combination with platinum-based chemotherapy as a first-line treatment for metastatic non-small cell lung cancer patients whose tumors lack EGFR mutations or ALK translocations.

Following CHMP's recommendation, the European Commission will review the opinion and decide whether to approve the regimen.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.


Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.


Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.


This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.